Alzheimer’s disease doesn’t arrive suddenly. Instead, it emerges slowly, beginning with subtle changes that might be dismissed as normal aging before progressing through increasingly serious stages of ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease’s progression - ...

Novo Nordisk's oral semaglutide drug failed in late-stage Alzheimer's trials, leading to a 10% drop in share price. The ...

Novo Nordisk's older oral semaglutide drug failed in late-stage trials aimed at slowing Alzheimer's cognitive decline, ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main ​goal in late-stage trials ...

The advent of amyloid-β (Aβ) and tau PET imaging has revolutionized Alzheimer disease (AD) research, enabling in vivo ...

Novo Nordisk (NVO) announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic ...

A Korean research team has identified the most effective OLED color capable of enhancing cognitive function in Alzheimer's ...